CA2622584C - Improvements in or relating to amphoteric liposomes - Google Patents

Improvements in or relating to amphoteric liposomes Download PDF

Info

Publication number
CA2622584C
CA2622584C CA2622584A CA2622584A CA2622584C CA 2622584 C CA2622584 C CA 2622584C CA 2622584 A CA2622584 A CA 2622584A CA 2622584 A CA2622584 A CA 2622584A CA 2622584 C CA2622584 C CA 2622584C
Authority
CA
Canada
Prior art keywords
mochol
dope
popc
amphoteric
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2622584A
Other languages
English (en)
French (fr)
Other versions
CA2622584A1 (en
Inventor
Steffen Panzner
Yvonne Kerwitz
Una Rauchhaus
Silke Lutz
Gerold Endert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adhera Therapeutics Inc
Original Assignee
Marina Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05020216A external-priority patent/EP1764089A1/en
Priority claimed from EP05020217A external-priority patent/EP1764090A1/en
Priority claimed from US11/267,423 external-priority patent/US20060159737A1/en
Priority claimed from PCT/EP2005/011905 external-priority patent/WO2006048329A1/en
Application filed by Marina Biotech Inc filed Critical Marina Biotech Inc
Priority to CA2889540A priority Critical patent/CA2889540A1/en
Publication of CA2622584A1 publication Critical patent/CA2622584A1/en
Application granted granted Critical
Publication of CA2622584C publication Critical patent/CA2622584C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
CA2622584A 2005-09-15 2006-09-15 Improvements in or relating to amphoteric liposomes Active CA2622584C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2889540A CA2889540A1 (en) 2005-09-15 2006-09-15 Improvements in or relating to amphoteric liposomes

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US71719905P 2005-09-15 2005-09-15
US71729105P 2005-09-15 2005-09-15
US71729305P 2005-09-15 2005-09-15
EP05020216.7 2005-09-15
US60/717,293 2005-09-15
EP05020216A EP1764089A1 (en) 2005-09-15 2005-09-15 Serum stable liposomes comprising amphoter II lipid mixtures
EP05020217.5 2005-09-15
US60/717,291 2005-09-15
EP05020217A EP1764090A1 (en) 2005-09-15 2005-09-15 Amphoteric liposomes for local drug applications
US60/717,199 2005-09-15
EP05020218 2005-09-15
EP05020218.3 2005-09-15
EPPCT/EP2005/011908 2005-11-04
US11/267,423 US20060159737A1 (en) 2004-11-19 2005-11-04 Pharmaceutical compositions for local administration
EPPCT/EP2005/011905 2005-11-04
PCT/EP2005/011905 WO2006048329A1 (en) 2004-11-05 2005-11-04 Improvements in or relating to pharmaceutical compositions comprising an oligonucleotide as an active agent
US11/266,999 US20060216343A1 (en) 2004-11-05 2005-11-04 Pharmaceutical compositions comprising an oligonucleotide as an active agent
PCT/EP2005/011908 WO2006053646A2 (en) 2004-11-19 2005-11-04 Improvements in or relating to pharmaceutical compositions for local administration
US11/267,423 2005-11-04
US11/266,999 2005-11-04
EP05090322A EP1658839A1 (en) 2004-11-05 2005-11-21 Oligonucleotide/carrier combinations targeting CD40
EP05090322.8 2005-11-21
EP06113784.0 2006-05-10
EP06113784 2006-05-10
PCT/EP2006/009013 WO2007031333A2 (en) 2005-09-15 2006-09-15 Improvements in or relating to amphoteric liposomes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2889540A Division CA2889540A1 (en) 2005-09-15 2006-09-15 Improvements in or relating to amphoteric liposomes

Publications (2)

Publication Number Publication Date
CA2622584A1 CA2622584A1 (en) 2007-03-22
CA2622584C true CA2622584C (en) 2015-08-11

Family

ID=37631866

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2622584A Active CA2622584C (en) 2005-09-15 2006-09-15 Improvements in or relating to amphoteric liposomes
CA2889540A Abandoned CA2889540A1 (en) 2005-09-15 2006-09-15 Improvements in or relating to amphoteric liposomes

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2889540A Abandoned CA2889540A1 (en) 2005-09-15 2006-09-15 Improvements in or relating to amphoteric liposomes

Country Status (7)

Country Link
US (3) US20070104775A1 (cg-RX-API-DMAC7.html)
EP (1) EP1764091B1 (cg-RX-API-DMAC7.html)
JP (1) JP5571308B2 (cg-RX-API-DMAC7.html)
KR (1) KR20080082956A (cg-RX-API-DMAC7.html)
AU (1) AU2006291429B2 (cg-RX-API-DMAC7.html)
CA (2) CA2622584C (cg-RX-API-DMAC7.html)
WO (1) WO2007031333A2 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
US8815599B2 (en) * 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
AU2006291429B2 (en) * 2005-09-15 2013-04-04 Biontech Delivery Technologies Gmbh Improvements in or relating to amphoteric liposomes
PL1957044T3 (pl) * 2005-12-01 2013-11-29 Pronai Therapeutics Inc Amfoteryczny preparat liposomowy
EP2004141A2 (en) * 2006-03-17 2008-12-24 Novosom AG An efficient method for loading amphoteric liposomes with nucleic acid active substances
CN101500616A (zh) * 2006-08-04 2009-08-05 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
CA2665783C (en) 2006-10-13 2015-12-15 Novosom Ag Improvements in or relating to amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
WO2008103431A2 (en) * 2007-02-23 2008-08-28 Pronai Therapeutics, Inc. Dnai - liposomes
GB0719367D0 (en) 2007-10-03 2007-11-14 Procarta Biosystems Ltd Transcription factor decoys, compositions and methods
AU2008309880B2 (en) * 2007-10-12 2014-07-10 Biontech Delivery Technologies Gmbh Amphoteric liposomes comprising neutral lipids
WO2009082491A1 (en) * 2007-12-26 2009-07-02 Alp Life Sciences, Llc Nanovesontm: treatment, biomarkers and diagnostic tests for liver diseases and comorbid diseases
US8900627B2 (en) * 2008-06-06 2014-12-02 Mirna Therapeutics, Inc. Compositions for the in vivo delivery of RNAi agents
JP5588619B2 (ja) 2009-03-11 2014-09-10 一丸ファルコス株式会社 ｐＨ応答性リポソーム
WO2011017297A2 (en) 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
GB201002413D0 (en) 2010-02-12 2010-03-31 Procarta Biosystems Ltd Nucleic acid complexes
GB201005545D0 (en) 2010-04-01 2010-05-19 Procarta Biosystems Ltd Transcription factor decoys
IT1404011B1 (it) 2010-12-03 2013-11-08 Uni Degli Studi Magna Graecia Di Catanzaro Nanovettore coniugato con tsh per il trattamento del cancro della tiroide
AU2012236099A1 (en) * 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
SI2854769T1 (sl) 2012-07-05 2023-09-29 Taiwan Liposome Company, Ltd. Postopki za zdravljenje artritisa
BE1022518B1 (fr) * 2014-03-12 2016-05-19 Glaxosmithkline Biologicals S.A. Formulation liposomale immunogene
CA2957618A1 (en) 2014-08-04 2016-02-11 MiRagen Therapeutics, Inc. Inhibitors of myh7b and uses thereof
US9376681B2 (en) 2014-09-08 2016-06-28 MiRagen Therapeutics, Inc. miR-29 mimics and uses thereof
EP3247716A4 (en) 2015-01-20 2018-10-17 Miragen Therapeutics, Inc. Mir-92 inhibitors and uses thereof
KR20190118688A (ko) 2015-06-05 2019-10-18 미라젠 세러퓨틱스 인코포레이티드 피부 t 세포 림프종(ctcl) 치료용 mir-155 억제제
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
EP3632403A4 (en) * 2017-05-23 2021-03-10 TCI Co., Ltd. EMULSIFIED LIPOSOME COMPOSITION AND PROCESS FOR PREPARATION
US20200208152A1 (en) 2017-09-08 2020-07-02 Mina Therapeutics Limited Stabilized sarna compositions and methods of use
EP3775211B1 (en) 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
EP3953473A1 (en) 2019-04-12 2022-02-16 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
TW202305133A (zh) 2021-03-26 2023-02-01 英商米納治療有限公司 Tmem173 sarna組合物及其使用方法
JP7761921B2 (ja) * 2021-05-21 2025-10-29 国立大学法人北海道大学 脂質ナノ粒子
AU2022378579A1 (en) 2021-10-28 2024-05-02 Lyell Immunopharma, Inc. Methods of generating cells
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024125597A1 (en) 2022-12-14 2024-06-20 Providence Therapeutics Holdings Inc. Compositions and methods for infectious diseases
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
WO2026006604A1 (en) 2024-06-26 2026-01-02 Lyell Immunopharma, Inc. Feeder cell replacement
WO2026027887A2 (en) 2024-08-02 2026-02-05 Mina Therapeutics Limited Hbg1/2-sarna compositions and methods of use

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
DE69429337T3 (de) * 1993-04-02 2012-08-30 Anticancer Inc. Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
US5834012A (en) * 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
JPH09248182A (ja) * 1996-03-15 1997-09-22 Oyo Seikagaku Kenkyusho プラスミド包埋多重膜リポソーム
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
EP0979311A1 (en) * 1997-04-30 2000-02-16 Of The University Of Minnesota Regents $i(IN VIVO) USE OF RECOMBINAGENIC OLIGONUCLEOBASES TO CORRECT GENETIC LESIONS IN HEPATOCYTES
AU733310C (en) * 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US6197584B1 (en) 1998-05-01 2001-03-06 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 expression
WO2000021370A1 (en) * 1998-10-14 2000-04-20 University Of Kentucky Research Foundation Oligonucleotide delivery systems for camptothecins
US6379698B1 (en) * 1999-04-06 2002-04-30 Isis Pharmaceuticals, Inc. Fusogenic lipids and vesicles
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
DE10109898A1 (de) 2001-02-21 2002-09-05 Novosom Gmbh Lipide mit veränderlicher Ladung
US20040086558A1 (en) * 2001-02-22 2004-05-06 Moshe Baru Liposome mediated dna administration
ES2340499T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
DE10207177A1 (de) 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
DE10207178A1 (de) 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
WO2003097805A2 (en) * 2002-05-15 2003-11-27 California Pacific Medical Center Delivery of nucleic acid-like compounds
AU2002953285A0 (en) * 2002-12-12 2003-01-02 Protech Research Pty Ltd Yeast treatment
WO2004090108A2 (en) 2003-04-03 2004-10-21 Alnylam Pharmaceuticals Irna conjugates
CA2532228C (en) * 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
WO2006048329A1 (en) * 2004-11-05 2006-05-11 Novosom Ag Improvements in or relating to pharmaceutical compositions comprising an oligonucleotide as an active agent
JP2008520600A (ja) 2004-11-19 2008-06-19 ノヴォソム アクチェンゲゼルシャフト 局所投与のための医薬組成物におけるまたはそれに関する改善
EP1764090A1 (en) 2005-09-15 2007-03-21 Novosom AG Amphoteric liposomes for local drug applications
EP1764089A1 (en) 2005-09-15 2007-03-21 Novosom AG Serum stable liposomes comprising amphoter II lipid mixtures
AU2006291429B2 (en) * 2005-09-15 2013-04-04 Biontech Delivery Technologies Gmbh Improvements in or relating to amphoteric liposomes

Also Published As

Publication number Publication date
CA2889540A1 (en) 2007-03-22
US20150231073A1 (en) 2015-08-20
US9066867B2 (en) 2015-06-30
EP1764091B1 (en) 2017-08-30
AU2006291429B2 (en) 2013-04-04
EP1764091A3 (en) 2007-06-13
CA2622584A1 (en) 2007-03-22
JP5571308B2 (ja) 2014-08-13
EP1764091A2 (en) 2007-03-21
AU2006291429A1 (en) 2007-03-22
US20070104775A1 (en) 2007-05-10
JP2009507876A (ja) 2009-02-26
US20110076322A1 (en) 2011-03-31
WO2007031333A3 (en) 2007-07-19
WO2007031333A2 (en) 2007-03-22
KR20080082956A (ko) 2008-09-12
US9737484B2 (en) 2017-08-22

Similar Documents

Publication Publication Date Title
CA2622584C (en) Improvements in or relating to amphoteric liposomes
US20060159737A1 (en) Pharmaceutical compositions for local administration
US20060216343A1 (en) Pharmaceutical compositions comprising an oligonucleotide as an active agent
Lasic Recent developments in medical applications of liposomes: sterically stabilized liposomes in cancer therapy and gene delivery in vivo
EP2773326B1 (en) Method for sterilely producing lipid-nucleic acid particles
US20140056970A1 (en) Efficient method for loading amphoteric liposomes with nucleic acid active substances
US20170152516A1 (en) Method of producing lipid nanoparticles for drug delivery
JP2011503070A (ja) 全身遺伝子送達のための自己構築型ミセル様ナノ粒子
CN102824647A (zh) 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法
WO2022037465A1 (zh) 一种脂质纳米颗粒
Haynes et al. Lipid-coated calcium phosphate nanoparticles for nonviral gene therapy
EP1764089A1 (en) Serum stable liposomes comprising amphoter II lipid mixtures
EP1764090A1 (en) Amphoteric liposomes for local drug applications
Sharma et al. Liposomes: vesicular system an overview
Escriou et al. Auto-associative lipid-based systems for non-viral nucleic acid delivery
HK40060954A (en) Lipid nanoparticle
CN119792238A (zh) 具有长期稳定性的核酸纳米制剂及其制备方法和应用
WO1999058111A1 (en) Methods of using lipid based drug delivery vehicles
Escrioua et al. AUTO-ASSOCIATIVE SYSTEMS FOR NON-VIRAL NUCLEIC ACID DELIVERY LIPIDS
Haynes et al. 1. RECENT PROGRESS OF NONVIRAL GENE THERAPY AND In vitro/In vivo DELIVERY SYSTEMS

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240826

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240826

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250905